Subcutaneous vs. IM Testosterone: what the PK data says

For decades, testosterone cypionate and enanthate were injected intramuscularly (IM) — into the glute, quad, or deltoid — because that's how the original FDA labeling read. Over the last ten years, subcutaneous (subQ) injection has quietly become the default for a lot of TRT clinicians. The question worth asking isn't which route is trendier. It's what the pharmacokinetic data actually shows about peaks, troughs, estradiol conversion, and side-effect burden.

This article walks through the published PK studies, the tradeoffs that matter clinically, and how to think about picking a route with your provider.

Why the injection route matters at all — in plain English

Testosterone cypionate and enanthate are esterified oil-based depots. Once injected, the ester slowly hydrolyzes and testosterone releases into circulation. The rate of that release depends on two things: the ester chain length (fixed) and the tissue you deposited the oil into (variable).

Muscle is more vascular than subcutaneous fat. So IM injections tend to release testosterone faster — higher early peak, faster decline. SubQ deposits sit in adipose tissue, which has a slower and more sustained absorption profile.

This matters because a lot of the side effects TRT patients complain about — mood swings, water retention, elevated estradiol, hematocrit creep — track more closely with peak-to-trough variability than with average testosterone levels.

What the pharmacokinetic studies actually show

The most-cited head-to-head data comes from a handful of trials over the past decade:

• Kaminetsky et al. (2019) studied subcutaneous testosterone enanthate auto-injector weekly dosing. Steady-state total testosterone stayed within the eugonadal range (300–1100 ng/dL) in the large majority of patients, with a lower Cmax than historical IM data.
• Spratt et al. (2017) compared subQ vs. IM testosterone cypionate in transgender men and found comparable total testosterone exposure (AUC) with subQ producing a smoother curve.
• Turner et al. (2019) found subQ testosterone in hypogonadal men achieved therapeutic levels with a favorable pharmacokinetic profile and low injection-site reaction rates.

The consistent signal across studies: AUC (total exposure) is similar between routes, but subQ blunts the peak and raises the trough, giving a flatter curve at equivalent weekly doses.

If you graphed a week of testosterone levels, IM looks like a mountain. SubQ looks like a hill.

Does subQ actually lower estradiol and hematocrit?

This is where the data gets more interesting — and more contested.

Mechanistically, aromatase (the enzyme that converts testosterone to estradiol) is concentration-dependent. Higher testosterone peaks drive higher estradiol peaks. So a flatter curve should, in theory, produce lower peak estradiol and less variability in symptoms like water retention, nipple sensitivity, or mood.

Some observational data supports this. Clinicians who switch patients from IM to subQ at the same weekly dose often report lower estradiol and modestly lower hematocrit on follow-up labs. But we don't have a large randomized trial confirming a clinically meaningful difference in erythrocytosis rates. Consider it a reasonable inference, not a settled fact.

{callout: The bottom line} At equivalent weekly doses, subcutaneous and intramuscular testosterone injections produce similar total exposure — but subQ tends to flatten the peak-to-trough curve, which for many patients means fewer symptom swings and a gentler estradiol response.

Frequency matters as much as route

One of the more overlooked findings in the PK literature is that injection frequency affects the curve more than route does.

A once-weekly IM injection of 100–200 mg cypionate produces a sharp peak around day 2–3 and a meaningful trough by day 7. Splitting that same weekly dose into two injections (every 3.5 days) — whether IM or subQ — dramatically flattens the curve. Splitting into three or more (EOD-style) flattens it further.

So the practical hierarchy looks like:

• Once-weekly IM → highest peaks, deepest troughs
• Once-weekly subQ → moderate peaks, moderate troughs
• Twice-weekly subQ → flat, steady state for most patients
• More frequent → diminishing returns, more needles

Most clinicians land on twice-weekly subQ as the sweet spot between tolerability and adherence. Standard published titration ranges for testosterone cypionate in adult men are roughly 50–200 mg per week total, adjusted based on symptoms and follow-up labs.

Practical tradeoffs — what actually changes day to day

Beyond the pharmacokinetics, the practical differences matter:

Needle size and comfort. SubQ uses a 27–30G, 1/2-inch insulin-style needle into the abdomen or thigh. IM uses a 22–25G, 1–1.5-inch needle into a deep muscle. SubQ is dramatically less painful and easier to self-administer.

Injection site reactions. SubQ can cause small nodules or transient redness at the site, especially early on. Rotating sites and warming the oil before injection helps. IM injections rarely cause visible reactions but can cause deeper post-injection soreness.

Volume limits. SubQ tolerates roughly 0.5–1 mL per site comfortably. IM tolerates larger volumes. For most TRT weekly doses in cottonseed or grapeseed oil, this isn't a constraint.

Absorption in lean vs. higher-body-fat patients. In very lean patients with minimal subcutaneous tissue, subQ technique matters more — pinching the skin properly and avoiding intradermal injection. In higher-body-fat patients, absorption may be marginally slower but still clinically effective.

What labs to watch either way

Regardless of route, the markers worth tracking on a testosterone protocol include:

• Total and free testosterone — drawn at trough (right before your next injection) to see the low point of your curve
• Estradiol (sensitive assay) — the LC-MS/MS version, not the standard immunoassay
• Hematocrit and hemoglobin — the most common reason to adjust dose or frequency
• SHBG — helps interpret free testosterone
• PSA — baseline and periodic monitoring in age-appropriate men
• Lipid panel and metabolic markers — worth trending over time

If you choose to do bloodwork through DirectCare AI, these are the markers we prioritize on a TRT panel. A thorough workup would typically include the above at baseline and then a follow-up panel 8–12 weeks after any dose or route change, once levels have reached steady state.

So which route should you pick?

Honest answer: for most patients, subcutaneous twice-weekly is a reasonable starting point because it minimizes needles, minimizes peak-driven side effects, and produces a steady curve. But IM is not wrong. Patients who've been on weekly IM for years with good labs and no symptoms don't need to switch.

The decision should be made with a clinician who's looking at your symptoms, your history, and — when you have them — your labs. Route is one lever. Frequency, dose, and ester choice are the others. The goal is a stable eugonadal range with minimal side effects, not a specific number on a specific day.

Compounded testosterone products are not FDA-approved as finished products; see the site disclaimer for details on compounded medication regulation.

References worth reading

• Kaminetsky J, et al. J Sex Med. 2019. Subcutaneous testosterone enanthate auto-injector pharmacokinetics.
• Spratt DI, et al. Andrology. 2017. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection.
• Turner L, et al. Endocr Pract. 2019. Subcutaneous testosterone administration in hypogonadal men.
• Bhasin S, et al. J Clin Endocrinol Metab. 2018. Testosterone therapy in men with hypogonadism: Endocrine Society clinical practice guideline.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.